Repligen (RGEN) to Buyback Up to 1.25M Shares
More News related to RGEN
- Repligen to Present at the 2008 UBS Global Life Sciences Conference Wednesday, September 24th, 1:00 p.m. EDT
- Repligen Announces Publication of Positive Results with Proprietary HDAC Inhibitor in Huntington's Disease Model
- Repligen (RGEN) Receives Research Grants to Support Friedreich's Ataxia Development Program
- Repligen Receives Research Grants to Support Friedreich's Ataxia Development Program
- Repligen Reports First Quarter Fiscal Year 2009 Financial Results
More News related to Stock Buybacks
- Spectrum Control (SPEC) Adds $5M to Buyback Program
- HealthTronics (HTRN) Acquires Ocean Radiation Therapy; Guides Q3; Approves $10M Buyback Program
- Red Hat (RHT) Increases Stock and Debenture Repurchase Plan By $85M
- American Physicians Service (AMPH) Announces $4M Share Buyback
- Basic Energy Services (BAS) Announces $50M Share Buyback
Repligen Corporation (Nasdaq: RGEN) today announced that its Board has authorized the repurchase of up to 1.25 million shares of its common stock. The Company currently has 31.2 million shares outstanding and the stock repurchases will be funded through available cash.
Repligen Corporation develops novel therapeutics primarily for the treatment of diseases of the central nervous system.
Related Categories
Stock BuybacksStocks Mentioned
-0.36Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
